Utility of the Cardiac Electrical BiomarkerDisease

Clinical Trials.gov
09 Dec, 2019 ,

Bev Hoddell, Milton Keynes University Hospital NHS Foundation Trust is conducting an Observational study in 800 participants in order to identify the diagnostic utility CEB (Cardiac Electrical Biomarker) in patients who are undergoing cardiac investigations.

Full content

This project is aiming to identify the diagnostic utility of an ECG derived measurement by a Medical device (Vectraplex by VectraCor ltd) in patients who are undergoing cardiac investigations. This technology is based on the principle of vector ECG and an analysing system that computes a composite score termed a Cardiac Electrical Biomarker (CEB TM).

CEB has been validated in the detection of STEMI with high sensitivity and specificity in the detection ECG changes characteristic to STEMI. The CEB may be a more accurate way of identifying heart injury and causes of chest pain compared to standard tests, which could lead to faster diagnosis and treatment of these patients.

The diagnostic utility of the CEBTM in the following:

  1. Acute chest pain assessment in the A&E department.
  2. Acute chest pain assessment in the Primary Care Surgery.
  3. Performance of CEB during inducible ischaemia in patients with stable angina
  4. Performance of CEB during acute ischaemia in patients undergoing percutaneous coronary intervention (PCI)
  5. Performance of CEB in patients undergoing cardio-toxic treatment